In a dramatic turn of events, aTyr Pharma, Inc. finds itself at the center of a class action lawsuit following the disappointing results of its Efzofitimod trial. Shareholders are seeking to recoup losses incurred between January 16, 2025, and September 12, 2025, due to alleged securities fraud. The lawsuit claims that aTyr misled investors with overly optimistic statements about the drug’s potential, particularly its ability to allow patients to completely taper off steroids.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The truth came to light on September 15, 2025, when aTyr revealed in an investor call that the EFZO-FIT study failed to meet its primary endpoint. The announcement, which highlighted the study’s inability to show a significant change from baseline in mean daily OSC dose at week 48, sent shockwaves through the market. Consequently, aTyr’s stock plummeted from $6.03 to $1.02 per share, marking an 83.2% drop in just one day.
For those who suffered losses during this period, there is an opportunity to seek recovery. Affected investors are encouraged to visit https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?wire=18 to learn more about their rights. Participation comes with no cost or obligation.
Renowned for its strength in securities litigation, Levi & Korsinsky LLP is committed to securing justice for all plaintiffs. With over 20 years of experience and a track record of recovering hundreds of millions for shareholders, the firm stands as a formidable advocate for investors. Levi & Korsinsky’s reputation is further solidified by its consistent ranking in the ISS Securities Class Action Services’ Top 50 Report.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171